Cilengitide is a new type of anti-cancer drug synthesized artificially. Merck Company's research has found that cilengitide combined with radiotherapy and chemotherapy (including concurrent and adjuvant temozolomide combined with radiotherapy) may prolong survival time. As the first integrin inhibitor anti-tumor drug, it has entered the III phase clinical trial. Its important mechanism is to target tumor by hindering blood vessel growth and providing nutrients to tumors, as well as promoting the growth of cancer cells through the blood supply structures that supply nutrients to tumors.
Basic Information
English name: Cilengitide
Company number: GT-F053
CAS number: 188968-51-6
Sequence: cyclo(Arg-Gly-Asp-D-Phe-N-Me-Val)
Molecular formula: C27H40N8O7
Molecular weight: 588.66
Preparation method of cilengitide
At present, the main preparation methods of cilengitide include liquid-phase synthesis process, solid-phase synthesis precursor peptide in liquid-phase ring formation process, and solid-phase synthesis process. Among them, the first two synthesis processes are that the precursor peptide synthesized is ringed in the liquid phase. This method requires the reactants to react in extremely dilute solvents (10³~10⁴ mol/L), and the molecules are prone to react with each other to form linear or cyclic polymers, which greatly reduces the ring formation yield and brings troubles to the subsequent purification. Moreover, in large-scale production, a large amount of waste liquid is generated, which is not conducive to industrial production. Based on the structure of cilengitide, using the principle of solid-phase pseudo-dilution effect, an efficient ring formation technology has been developed. The ring formation time is shortened to 20% - 30% of the liquid-phase ring formation, and the solvent used in the reaction is 2% - 8% of the liquid-phase solvent.
